Hematological Oncology : Impact Factor & More
eISSN: 1099-1069pISSN: 0278-0232
Share this on:
Key Metrics
CiteScore 
5.3
Eigenfactor
0.001 - 0.005
Impact Factor
< 5
SJR
Q3Oncology
SNIP
1.04
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Hematological Oncology
Hematological Oncology Journal Specifications
| Overview | |
| Publisher | WILEY |
| Language | English |
| Frequency | Quarterly |
| General Details | |
| Language | English |
| Frequency | Quarterly |
| Publication Start Year | 1983 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Hematological Oncology ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Hematological Oncology
Low-Dose Golidocitinib for Triple-Mutant (JAK1/STAT3/TET2) ITLPD-GI After DLBCL Remission.
- 1 Jul 2026
- Hematological oncology
Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.
- 1 Jul 2026
- Hematological oncology
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.
- 1 Jul 2026
- Hematological oncology
Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.
- 1 Jul 2026
- Hematological oncology
Identification of miR-107 and miR-451-a as Prognostic Biomarkers in Acute Myeloid Leukemia.
- 1 Jul 2026
- Hematological oncology
Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.
- 1 Jul 2026
- Hematological oncology
Low-Dose Golidocitinib for Triple-Mutant (JAK1/STAT3/TET2) ITLPD-GI After DLBCL Remission.
- 1 Jul 2026
- Hematological oncology
Sustained Complete Response in Refractory Idiopathic Multicentric Castleman Disease Following a Single CD19 CAR T-Cell Infusion: A Case Report With Mechanistic Insight.
- 1 Jul 2026
- Hematological oncology
Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series.
- 1 Jul 2026
- Hematological oncology
Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.
- 1 Jul 2026
- Hematological oncology
Identification of miR-107 and miR-451-a as Prognostic Biomarkers in Acute Myeloid Leukemia.
- 1 Jul 2026
- Hematological oncology
Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real-World Study.
- 1 Jul 2026
- Hematological oncology
FAQs on Hematological Oncology
How long has Hematological Oncology been actively publishing? 
What is the publishing frequency of Hematological Oncology?
How many articles did Hematological Oncology publish last year?
What is the eISSN & pISSN for Hematological Oncology?
What is Citescore for Hematological Oncology?
What is SNIP score for Hematological Oncology?
What is the SJR for Hematological Oncology?
Who is the publisher of Hematological Oncology?
